Should a patient with systemic lupus erythematosus (SLE) and pulmonary nodules, being treated with hydroxychloroquine (Plaquenil), who presents with hyperpyrexia, but has a normal white blood cell count and no obvious signs of infection, be given antibiotics?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

I would not immediately start antibiotics for this patient with lupus who has a single fever measurement of 39°C, pulmonary nodules, normal white blood cell count, normal leukocytes, and no obvious signs of infection. Instead, I would recommend close monitoring and further evaluation to determine the cause of the fever. The pulmonary nodules in a lupus patient on hydroxychloroquine could represent lupus-related inflammation rather than infection, and the single fever spike without other signs of infection suggests a possible lupus flare. Before starting antibiotics, I would obtain blood cultures, urinalysis, chest imaging, and possibly bronchoscopy if the pulmonary nodules are concerning. Empiric antibiotics without clear evidence of infection can lead to unnecessary side effects, antimicrobial resistance, and might mask the true underlying cause. If the patient's condition worsens, develops additional signs of infection, or if cultures return positive, then targeted antibiotic therapy would be appropriate. The decision to withhold antibiotics initially is based on balancing the risks of untreated infection against the harms of unnecessary antibiotic use, particularly in an immunocompromised patient where the fever could be due to the underlying autoimmune disease, as suggested by 1. It's also worth noting that the use of hydroxychloroquine, which the patient is already on, has shown potential antiviral effects and may be beneficial in the management of COVID-19, as mentioned in 1 and 1. However, the primary concern in this case is to determine the cause of the fever and to avoid unnecessary antibiotic use, as recommended in 1. Some key points to consider in this case include:

  • The patient's normal white blood cell count and normal leukocytes, which suggest that there may not be an underlying infection
  • The presence of pulmonary nodules, which could represent lupus-related inflammation or infection
  • The patient's single fever measurement of 39°C, which could be due to a lupus flare or other non-infectious cause
  • The potential benefits and risks of antibiotic use in an immunocompromised patient, as discussed in 1. Overall, a cautious approach is warranted, with close monitoring and further evaluation to determine the cause of the fever and to guide treatment decisions.

From the Research

Patient Presentation

  • The patient has lupus and pulmonary nodules, and is currently on hydroxychloroquine.
  • The patient has a fever of 39, but normal white blood cell count and normal leukocytes.
  • There are no obvious signs of infection.

Considerations for Immunocompromised Patients

  • Immunocompromised patients, such as those with lupus, are at increased risk of complications from infection 2.
  • However, the patient's normal white blood cell count and lack of obvious signs of infection suggest that antibiotics may not be immediately necessary.

Treatment of Systemic Lupus Erythematosus

  • Hydroxychloroquine is a standard treatment for SLE and has been associated with a significant reduction in mortality 3, 4, 5.
  • The treatment goals for SLE include reducing disease exacerbations, hospitalizations, and organ damage due to the disease or treatment toxicity 3.

Infection Risk in Immunocompromised Patients

  • Immunocompromised patients are at increased risk of invasive fungal infections, particularly those caused by Aspergillus species, mucormycetes, Cryptococcus species, and Candida species 6.
  • However, there is no clear evidence to suggest that the patient's fever is due to an invasive fungal infection.

Decision to Give Antibiotics

  • Given the patient's normal white blood cell count and lack of obvious signs of infection, it is unclear whether antibiotics are necessary.
  • Further evaluation and monitoring of the patient's condition may be necessary to determine the cause of the fever and the appropriate course of treatment.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Infectious disease considerations in immunocompromised patients.

JAAPA : official journal of the American Academy of Physician Assistants, 2020

Research

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Therapeutic advances in musculoskeletal disease, 2022

Research

Treatment of systemic lupus erythematosus.

Australian prescriber, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.